Alnylam's Amvuttra shows sustained benefit in five-year ATTR-CM study data
ALNY•ALNY•ALNY•ALNY•Alnylam Pharmaceuticals presented five-year HELIOS-B results showing continuous Amvuttra treatment reduced mortality and cardiovascular events compared with starting treatment approximately three years later. Earlier treatment better preserved quality of life, with no new safety signals through five years.
Alnylam Pharmaceuticals presented five-year HELIOS-B results for Amvuttra in transthyretin amyloidosis with cardiomyopathy at the American Heart Association Scientific Sessions 2026. Continuous treatment reduced mortality and cardiovascular events compared with starting treatment approximately three years later.
Earlier treatment better preserved quality of life, and no new safety signals were identified through five years. A separate exploratory analysis found Amvuttra preserved exercise capacity over two years compared with placebo.
